Or Metastatic Nras-mutant Melanoma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS research · 2026-02-27
Clinical Trial Update: A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) [Phase 3]
A Phase 3 trial SEACRAFT-2 evaluating naporafenib plus trametinib in NRAS-mutant melanoma is currently active but not recruiting.